Edgtton Kristy L, Gow Renae M, Kelly Darren J, Carmeliet Peter, Kitching A Richard
Centre for Inflammatory Diseases, Monash University, Department of Medicine, Monash Medical Centre, Clayton, Victoria, Australia.
Kidney Int. 2004 Jul;66(1):68-76. doi: 10.1111/j.1523-1755.2004.00707.x.
The plasminogen-plasmin system has potential beneficial or deleterious effects in the context of renal fibrosis. Recent studies have implicated plasminogen activators or their inhibitors in this process.
The development of renal interstitial fibrosis was studied in mice genetically deficient in plasminogen (plg-/- mice) and littermate controls (plg+/+ mice) by inducing unilateral ureteric obstruction (UUO) by ligating the left ureter.
Collagen accumulation in the kidney was decreased in plg-/- mice at 21 days compared with plg+/+ mice by hydroxyproline assay (plg+/+ 19.0 +/- 1.2 microg collagen/mg tissue, plg-/- 15.6 +/- 0.5 microg collagen/mg tissue, P= 0.04). Macrophage accumulation in plg-/- mice was reduced at 21 days, consistent with a role for plasmin in macrophage recruitment in this model. Myofibroblast accumulation, assessed by the expression of alpha-smooth muscle actin (alpha-SMA), was similar in both groups at both time points. Endogenous plasmin played a role in the activation of transforming growth factor-beta (TGF-beta), as plg-/- mice had lower ratios of betaig-h3:TGF-beta1 mRNA than plg+/+ mice. Matrix metalloproteinase (MMP)-9 activity was unchanged in the absence of plasmin, but MMP-2 activity was decreased.
Plasminogen, the key proenzyme in the plasminogen-plasmin system, does not protect mice from experimental interstitial fibrosis and may have significant pathogenetic effects. These findings, together with other recently published studies in the biology of renal fibrosis, imply that effects of proteins such as plasminogen activator inhibitor-1 (PAI-1), tissue-type plasminogen activator (tPA), and urokinase-type plasminogen activator receptor (uPAR) on renal fibrosis occur independently from the generation of plasmin.
纤溶酶原-纤溶酶系统在肾纤维化过程中可能具有有益或有害的作用。最近的研究表明纤溶酶原激活剂或其抑制剂参与了这一过程。
通过结扎左输尿管诱导单侧输尿管梗阻(UUO),研究纤溶酶原基因缺陷小鼠(plg-/-小鼠)和同窝对照小鼠(plg+/+小鼠)肾间质纤维化的发展情况。
通过羟脯氨酸测定,与plg+/+小鼠相比,plg-/-小鼠在21天时肾脏中的胶原积累减少(plg+/+为19.0±1.2μg胶原/毫克组织,plg-/-为15.6±0.5μg胶原/毫克组织,P = 0.04)。在21天时,plg-/-小鼠中的巨噬细胞积累减少,这与纤溶酶在该模型中巨噬细胞募集的作用一致。通过α-平滑肌肌动蛋白(α-SMA)表达评估的肌成纤维细胞积累在两个时间点的两组中相似。内源性纤溶酶在转化生长因子-β(TGF-β)的激活中起作用,因为plg-/-小鼠的βig-h3:TGF-β1 mRNA比值低于plg+/+小鼠。在没有纤溶酶的情况下,基质金属蛋白酶(MMP)-9活性未改变,但MMP-2活性降低